特别提示： 1、截至 2025 年 9 月 26 日，康泰医学系统（秦皇岛）股份有限公司（以下 简称"公司"）股票已出现任意连续三十个交易日中至少有十五个交易日的收盘 价低于"康医转债"当期转股价格的 85%的情形，触发"康医转债"转股价格向 下修正条款。 证券代码：300869 证券简称：康泰医学 公告编号：2025-073 债券代码：123151 债券简称：康医转债 康泰医学系统（秦皇岛）股份有限公司 关于不向下修正"康医转债"转股价格的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 2、2025 年 9 月 26 日，公司召开第四届董事会第二十三次会议，审议通过 了《关于不向下修正"康医转债"转股价格的议案》，公司董事会决定本次不向 下修正"康医转债"转股价格，且在未来六个月内（即 2025 年 9 月 27 日至 2026 年 3 月 26 日），如再次触发"康医转债"转股价格的向下修正条款，亦不提出 向下修正方案。自 2026 年 3 月 27 日起算，若再次触发"康医转债"转股价格的 向下修正条款，届时公司董事会将再次召开会议决定是否行使"康 ...

Group 1 - In August, the total electricity consumption in China reached 10,154 billion kWh, a year-on-year increase of 5.0% [3] - The electricity consumption by the primary industry was 164 billion kWh, up 9.7% year-on-year; the secondary industry consumed 5,981 billion kWh, also up 5.0%; the tertiary industry saw a consumption of 2,046 billion kWh, increasing by 7.2% [3] - Cumulative electricity consumption from January to August was 68,788 billion kWh, a year-on-year growth of 4.6% [3] Group 2 - The Ministry of Industry and Information Technology reported that by the end of August, the total number of fixed broadband internet access users reached 689 million, with a net increase of 18.85 million users since the end of last year [4] - Users with internet access speeds of 100 Mbps and above accounted for 95.2% of total users, while those with speeds of 1,000 Mbps and above reached 233 million, representing 33.9% of total users [4] Group 3 - The State Administration for Market Regulation held discussions with Huo La La to ensure compliance with antitrust laws and promote fair market competition [4] - The National Internet Information Office took action against the Toutiao platform for failing to manage content responsibly, leading to penalties and required corrections [4][5] - The OECD projected a global economic growth rate of 3.2% for 2025, an increase of 0.3 percentage points from previous forecasts [4] Group 4 - Tianpu Co. announced that its stock would be suspended for further investigation due to a 15 consecutive trading limit increase [7] - Haili Co. refuted rumors regarding shell mergers and asset injections [7] - Guiguan Network denied rumors of a significant computing power collaboration with Huawei Cloud [8]

Group 1: Company Announcements - Ganli Pharmaceutical signed a technology transfer and supply agreement with FZ and BIOMM, with a total supply framework agreement amount expected to be no less than 3 billion RMB [1] - Upwind New Materials completed the transfer of 121 million shares, changing its controlling shareholder to Zhiyuan Hengyue, associated with Zhiyuan Robotics [2] - Poly Developments plans to publicly issue corporate bonds not exceeding 15 billion RMB for various purposes including debt repayment and project construction [3] Group 2: Shareholder Actions - Lenovo Holdings reduced its stake in Lakala by 8.0781 million shares, decreasing its ownership from 25.00% to 23.97% [4] - Fenghuo Communication plans to repurchase shares with a budget between 75 million and 150 million RMB, with a maximum repurchase price of 40.53 RMB per share [5] - Hualing Cable intends to acquire control of San Bamboo Intelligent for no more than 270 million RMB to enhance its capabilities in robotics and high-frequency transmission [6] Group 3: Market Developments - Guiguang Network clarified that rumors regarding major collaborations with Huawei Cloud and restructuring with state-owned enterprises are untrue [7] - Dongshan Precision is planning to issue H-shares and list on the Hong Kong Stock Exchange to enhance its international presence [8] - Wolong Nuclear Materials' subsidiary plans to invest up to 1 billion RMB in a new materials project in Suzhou [9] Group 4: Other Corporate Activities - Chao Xun Communication's management completed their share reduction plan, with specific shares sold by board members [10] - Various companies are involved in significant project bids and collaborations, including China Electric Research and others [15]

Core Viewpoint - 康泰医学 has recently obtained the CE certification for its Color Doppler Ultrasound Diagnostic System (CMS1700B, CMS1700C), indicating compliance with EU standards and market entry eligibility, which is expected to positively impact the company's future operations [1] Group 1 - The products CMS1700B and CMS1700C have received CE certification from DNV Product Assurance AS [1] - The CE certification signifies that the products meet relevant EU requirements [1] - The actual sales performance of the products will depend on future market promotion efforts, and the impact on the company's future revenue remains unpredictable [1]

Core Viewpoint - Kangtai Medical (300869) has recently obtained CE certification for its color Doppler ultrasound diagnostic systems (CMS1700B, CMS1700C), indicating compliance with EU regulations and market entry eligibility, which will positively impact the company's future operations [1] Group 1 - The CE certification was issued by DNV Product Assurance AS, confirming that the products meet relevant EU requirements [1] - The certification allows the company to access the European market, enhancing its growth opportunities [1] - The positive implications for the company's future operations are highlighted, suggesting potential revenue growth and market expansion [1]

Core Viewpoint - 康泰医学 has recently obtained the CE certificate for its Color Doppler Ultrasound Diagnostic System (CMS1700B, CMS1700C), indicating compliance with EU standards and market entry eligibility, which is expected to positively impact the company's future operations [1]. Company Summary - The product, Color Doppler Ultrasound Diagnostic System (CMS1700B, CMS1700C), has received certification from DNV Product Assurance AS [1]. - The CE certification signifies that the product meets the relevant EU requirements, allowing for access to the European market [1]. - This development is anticipated to have a beneficial effect on the company's future business operations [1].

Core Viewpoint - 康泰医学 has recently obtained the CE certificate for its Color Doppler Ultrasound Diagnostic System (CMS1700B, CMS1700C), indicating compliance with EU standards and market entry eligibility, which will positively impact the company's future operations [1] Company Summary - The product name is Color Doppler Ultrasound Diagnostic System (CMS1700B, CMS1700C) [1] - The CE certificate was issued by DNV Product Assurance AS, confirming that the product meets relevant EU requirements [1] - The acquisition of the CE certificate is expected to have a positive effect on the company's future business operations [1]

Core Viewpoint - The company has recently obtained a CE certificate for its Color Doppler Ultrasound Diagnostic System (CMS1700B, CMS1700C), indicating compliance with EU standards and market entry eligibility, which will positively impact future operations [1] Company Summary - The product name is Color Doppler Ultrasound Diagnostic System (CMS1700B, CMS1700C) [1] - The CE certificate was issued by DNV Product Assurance AS [1] - The certification signifies that the product meets relevant EU requirements [1] - The achievement of the CE certification is expected to have a positive effect on the company's future business operations [1]

证券代码：300869 证券简称：康泰医学 公告编号：2025-071 债券代码：123151 债券简称：康医转债 康泰医学系统（秦皇岛）股份有限公司 关于公司产品获得 CE 证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 康泰医学系统（秦皇岛）股份有限公司（以下简称"公司"）于近日取得了 由 DNV Product Assurance AS 签发的 CE 证书，具体情况如下： 产 品 名 称 ： Color Doppler Ultrasound Diagnostic System （ CMS1700B ， CMS1700C） 中文译名：彩色多普勒超声诊断系统（CMS1700B，CMS1700C） 证书编号：C6331117 注册分类：IIa 上述产品取得 CE 证书，表明了产品符合欧盟相关要求，已经具备欧盟市场 的准入条件，对公司未来经营将产生积极影响。上述产品实际销售情况取决于未 来市场推广效果，目前尚无法预测上述产品对公司未来营业收入的影响。敬请广 大投资者注意投资风险。 特此公告。 康泰医学系统（秦皇岛）股份有限公司董事会 2025 年 9 ...

（文章来源：证券日报） 证券日报网讯 9月22日晚间，康泰医学发布公告称，根据公司战略规划，为推动公司业务高质量发展， 完善公司产业布局，进一步提高综合竞争力，公司出资人民币500万元设立全资子公司医电精测技术服 务（秦皇岛）有限公司。公司本次全部以自有资金出资，持股比例为100%。近日，上述子公司完成了 工商注册登记手续，并取得了秦皇岛市市场监督管理局经济技术开发区分局颁发的《营业执照》。 ...